Previous 10 | Next 10 |
Mereo BioPharma Group plc (MREO) is expected to report for Q4 2023
2024-03-14 17:34:14 ET Summary Alpha-1 antitrypsin deficiency, or AATD, is an inherited disease that affects the lung, liver, and skin. The current treatment landscape involves smoking cessation, COPD treatment, and augmentation therapy with AAT. Newer therapies in development...
LONDON, March 05, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate ...
2024-01-16 09:45:09 ET Microsoft Corporation (MSFT) MSFT is trading UP for the last 5 days, and it at trading at $392.38 with volume of 9,037,995 and a one day change of $3.91 (1.01%). Microsoft Corporation has a 52-week low of 230.68 and a 52-week high of $390.68. The business's 50...
2024-01-08 08:40:02 ET More on Mereo BioPharma Group Mereo BioPharma: Lagging Stock Despite Positive Data Seeking Alpha’s Quant Rating on Mereo BioPharma Group For further details see: Mereo BioPharma provides update on pipeline progress, reaffirms cash ru...
Phase 3 portion of Orbit Study and Phase 3 Cosmic Study of setrusumab for treatment of Osteogenesis Imperfecta (OI) conducted by partner Ultragenyx expected to complete enrollment around the end of 1Q 2024 and 1H 2024, respectively; Additional Phase 2 data expected in 2024 Alignment on de...
2023-12-13 04:50:52 ET Summary Mereo BioPharma has shifted its focus from developing anti-TIGIT molecules to rare disease programs. The company's current pipeline includes programs for Osteogenesis Imperfecta, Alpha-1 Antitrypsin Deficiency-associated Lung Disease, and anti-TIGIT ...
2023-11-14 21:51:36 ET Summary Ultragenyx shows clinical innovation in rare diseases; financial growth is offset by high net loss and cash burn. Recent earnings indicate YOY revenue growth but a substantial net loss; operating expenses have decreased. Ultragenyx's liquid asset...
LONDON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on recent program developments and third quarter 2023 financial ...
2023-10-23 08:21:00 ET Textainer Group Holdings ( TGH ) +43% . Mynaric ( MYNA ) +17% . Navios Maritime Holdings ( NM ) +17% to buy N Logistics in $2.28/share all-cash deal. Next. ( EGOX ) +16% . Harpoon Therapeutics ( HARP ) ...
News, Short Squeeze, Breakout and More Instantly...
Mereo BioPharma Group Company Name:
MREO Stock Symbol:
NASDAQ Market:
Mereo BioPharma Group Website:
2024-06-20 09:00:06 ET Joseph Schwartz from Leerink Partners issued a price target of $8.00 for MREO on 2024-06-20 07:21:00. The adjusted price target was set to $8.00. At the time of the announcement, MREO was trading at $3.98. The overall price target consensus is at $...
2024-06-14 10:45:03 ET Cleanspark Inc (CLSK) CLSK is trading UP for the last 5 days, and it at trading at $18.30 with volume of 12,068,034 and a one day change of $0.33 (1.84%). Cleanspark Inc has a 52-week low of 3.38 and a 52-week high of $24.72. The business's 50-day moving avera...
LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the pricing of an underwritten offering of 12,531,300 of its American Dep...